1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Medical - Instruments & Supplies
Elekta AB (publ)

Elekta AB (publ)

EKTA-B.ST
Elekta AB (publ)SE flagStockholm Stock Exchange
50.30
SEK
+0.36
- -
18.47BMarket Cap
Elekta AB (publ)
EKTA-B.ST
(Stockholm Stock Exchange)

Recent

price

50.30

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
21.17
24.04
27.16
28.05
28.43
29.43
28.07
30.29
35.48
38.22
36.02
38.08
44.15
47.42
47.15
43.75
43.74
Revenue per Share
2.76
3.26
3.52
3.01
1.45
0.36
0.33
3.53
3.14
2.84
3.28
3.02
2.47
3.41
0.62
-1.36
-1.36
Basic EPS, GAAP
1.98
1.34
3.48
1.44
2.21
1.01
2.74
4.06
2.52
0.66
4.46
1.18
1.05
2.14
2.24
3.64
3.64
Free Cash Flow per Basic Share
0.75
1
1.27
2.02
2.02
0.51
0.53
1
1.4
1.8
1.8
2.2
2.4
2.4
2.4
2.4
2.4
Dividend per Share
9.88
12.08
14.1
15
14.43
14.3
10.92
13.4
15.05
15.76
17.69
18.52
18.59
19.63
17.89
- -
- -
Book Value per Share
3.06
-3.85
-2.27
-1.54
-4.01
-4.72
-8.24
-5.73
-3.99
-3.55
-1.53
-3.53
-5.21
-6.69
-8.03
-9.38
-9.37
Tangible Book Value per Share
373
376
381
381
381
381
381
382
382
382
382
382
382
382
382
382
382
Basic Weighted Avg Shares
7,904
9,048
10,339
10,694
10,839
11,221
10,704
11,573
13,555
14,601
13,763
14,548
16,869
18,119
18,016
16,718
16,717
Sales/Revenue/Turnover
17.83
19.62
19.75
16.9
8.96
10.57
12.29
15.59
13.1
13.39
13.15
10.23
11.06
12.47
5
0.6
0.62
Operating Margin (%)
241
295
349
414
512
634
655
675
943
1,275
1,204
1,039
1,062
1,136
1,300
1,249
1,250
Depreciation Expense
1,031
1,227
1,340
1,148
552
137
125
1,348
1,198
1,084
1,254
1,154
943
1,302
237
-519
-519
Net Income, GAAP
29.58
28.1
24.94
23.3
22.07
23.28
62.94
19.81
24.18
25.45
23.13
22.98
21.2
21.88
51.02
- -
48.19
Effective Tax Rate (%)
13.04
13.56
12.96
10.73
5.09
1.22
1.17
11.65
8.84
7.42
9.11
7.93
5.59
7.19
1.32
-3.1
-3.1
Profit Margin (%)
1,833
3,050
3,391
3,473
2,965
721
1,290
1,409
1,000
4,266
1,306
1,324
1,669
-38
1,069
-1,961
-1,961
Working Capital
782
4,417
4,340
4,361
4,958
3,065
5,272
4,369
3,558
8,144
3,897
4,940
6,418
5,902
7,156
4,138
4,138
LT Debt
3,833
5,009
5,560
6,257
6,645
6,412
5,561
6,987
7,778
8,113
8,195
8,915
9,733
10,780
8,847
7,148
7,148
Total Equity
21.22
17.57
15.37
13.07
6.42
7.58
4.4
12.52
10.97
9.66
8.49
7.68
9.22
9.93
2.47
- -
- -
Return on Invested Capital (%)
24.91
20.06
15.46
12.9
6.57
2.85
2.03
14.86
12.68
9.68
10.11
9.82
8.94
11.09
2.99
- -
8.17
Return on Capital (%)
30.85
29.79
27.02
20.71
9.84
2.5
2.6
29.05
22.05
18.42
19.62
16.68
13.3
17.83
3.31
-15.18
-15.18
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Oct'26
Jan'26
Apr'26
ST Debt
1,096
2,038
3,193
LT Borrowings
5,647
4,458
3,380
LT Finance Leases
859
788
758
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
382
382
382
Market Capitalization
18,485
21,873
20,354

Working Capital

FRC

•

in mil. unless spec.
Oct'26
Jan'26
Apr'26
Total Current Assets
13,034
13,030
13,102
Cash, Cash Equivalents & STI
2,576
2,541
3,189
Accounts Receivable, Net
3,324
3,772
3,688
Inventories
3,086
3,019
2,876
Total Current Liabilities
12,564
13,753
15,063
Payables & Accruals
- -
- -
- -
ST Debt
1,096
2,038
3,193
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.06%
-1.68%
-19.2%
Free Cash Flow
77.05%
17.38%
62.62%
Net Income, GAAP
57.57%
-77.79%
-318.99%
Sales/Revenue/Turnover
4.39%
4.26%
-7.2%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3,828
4,732
4,537
5,023
18,119
2025
3,825
4,341
4,695
5,156
18,016
2026
3,646
4,070
4,239
4,762
16,718

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.62
0.9
0.8
1.08
3.41
2025
0.18
0.55
0.89
-1.01
0.62
2026
0.28
0.6
0.03
-2.27
-1.36

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
1.2
- -
1.19
2.4
2025
- -
1.19
- -
1.2
2.4
2026
- -
1.19
- -
1.2
2.4
Similar Companies
Tristel PLC (TSTL.L)
Menicon Co Ltd (MECNY)
Ortivus AB (publ) (ORTI-A.ST)
SKAN Group AG (SKAN.SW)
Kangji Medical Holdings Limited (9997.HK)
Omega Diagnostics Group PLC (ODX.L)
Business
Elekta AB (publ) is a Sweden-based medical technology company specializing in the development, manufacturing, and sale of clinical solutions for the treatment of cancer and brain disorders. Its core products include advanced radiation therapy and radiosurgery systems such as linear accelerators (including the recently launched Elekta Evo, a CT-adaptive and AI-powered linac), the Leksell Gamma Knife for stereotactic radiosurgery, brachytherapy treatment solutions including applicators like the Rotterdam, and comprehensive clinical software systems like Elekta ONE that enhance workflow efficiency across cancer care. The company also offers products for image-guided radiation therapy and stereotactic radiosurgery that enable precise tumor and functional target treatment while sparing healthy tissue. Headquartered in Stockholm, Sweden, Elekta operates globally in more than 120 countries with around 4,700 employees. Recent major changes include the launch of the Elekta Evo linear accelerator and expansion of the Elekta ONE software suite, which together aim to drive higher personalization and productivity in radiation therapy. Elekta also acquired Philips Healthcare's Pinnacle Treatment Planning System patent portfolio to strengthen its software offerings. The company expanded operational presence by acquiring assets from its distributor in Croatia, enhancing market position and service delivery in Southeast Europe. Further strategic partnerships include an alliance with GE Healthcare's MIM Software to advance cancer care solutions. Elekta continues to innovate with products like the Elekta Esprit for neuro treatment and Elekta Harmony linac, maintaining its leadership in precision radiation therapy and clinical management for oncology and neurology. Founded in 1972, Elekta serves healthcare providers with sophisticated medical devices and software solutions aimed at improving, prolonging, and saving lives through precision cancer and brain disorder treatment. The company is listed on Nasdaq Stockholm under the ticker EKTA-B.ST. Its product portfolio spans radiation therapy equipment, radiosurgery devices, brachytherapy solutions, and integrated clinical software, targeting oncology centers, hospitals, and specialized clinics worldwide. Elekta's continued investment in innovation, strategic acquisitions, and market expansion positions it as a leading global player in the medical technology industry focused on cancer treatment and neurological disorders.